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Purpose or Objective: To compare radiation dosimetry of 
various cardiac structures and other thoracic tissue, such as 
lung fields and non-treated breast, associated with breast 
irradiation (left versus right-sided) in supine versus prone 
treatment positions. 
 
Material and Methods: Twenty-four post-lumpectomy 
patients (8 left-sided, 16 right-sided) underwent non-contrast 
2mm slice thickness radiotherapy (RT) planning CT scans in 
the supine and prone positions. Optimized tangential breast 
RT plans were generated. In all cases, prescribed RT dose 
was 50Gy in 2Gy daily fractions. Twenty specific structures 
(whole heart, atria and ventricles, major vessels, cardiac 
valves, epicardial coronary arteries including left anterior 
descending (LAD), ipsilateral/contralateral lung and non-
treated breast) were contoured on each CT dataset based on 
a published reference atlas. Maximum, minimum, mean doses 
and volume (cm³) were compared for all structures in both 
supine and prone positions. Whole heart V5, V25 and V30 as 
well as lung V20 were evaluated. The independent two-
sample t-test was used to determine the impact of treatment 
laterality and the paired t-test for the treatment positioning 
on RT dosimetry respectively, with p<0.05 considered 
significant. 
 
Results: Left compared to right-sided breast irradiation 
significantly increased maximum (p<0.001) and mean 
(p<0.001) whole heart dose, as well as doses to individual 
cardiac structures, in both prone and supine positions.  
Prone versus supine positioning significantly increased 
maximum whole heart dose 25.8Gy versus 19.2Gy (p=0.007) 
and mean LAD artery 8.4Gy vs. 5.0Gy respectively (p=0.03). 
Whole heart V5 (3.9 vs. 2.5%), V25 (1.4 vs. 0.8%), and V30 
(1.1 vs. 0.7%), did not differ significantly between prone and 
supine positions. Table 1 illustrates comparisons of other 
individual cardiac structures. As anticipated, maximum dose 
(48.5 vs. 50.3Gy), mean dose (3.3 vs. 6.5Gy) and V20 (5.3% 
vs. 11.5%) to the ipsilateral lung (p<0.001 for all comparisons) 
were reduced when patients were treated in the prone versus 
supine position. 
 
 
Conclusion: A statistically higher radiation dose was seen to 
the whole heart and various cardiac structures, including 
atria, ventricles and LAD artery, for left compared to right-
sided breast cancer patients. Furthermore, prone positioning 
increased maximum whole heart and LAD artery doses, 
despite its known benefit in reducing dose-volume effects to 
lung tissue. This is one of few studies to assess differential 
radiation doses to individual cardiac structures. 
 
Poster: Clinical track: Lung  
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Purpose or Objective: A prognostic model for non-small cell 
lung cancer (NSCLC) patients with validated clinical variables 
[gender, World Health Organization performance status, 
forced expiratory volume in 1 second, number of positive 
lymph node stations, and total gross tumor volume], and 
blood-biomarkers related to hypoxia [osteopontin (OPN) and 
carbonic anhydrase IX (CA-IX)], inflammation [interleukin-6 
(IL-6), IL-8, and C-reactive protein (CRP)], and tumor load 
[carcinoembryonic antigen (CEA), and cytokeratin fragment 
21-1 (Cyfra 21-1)] was developed and validated. Finally, the 
model was extended with alpha-2-macroglobulin (α2M), 
serum interleukin-2 receptor (sIL2r), toll-like receptor 4 
(TLR4), and vascular endothelial growth factor (VEGF). 
 
Material and Methods: The model was developed and 
validated on respectively 182 and 181 inoperable stage I-IIIB 
NSCLC patients treated radically with (chemo)radiotherapy. 
It included the mentioned clinical features, and blood-
biomarkers were selected by least absolute shrinkage and 
selection operator (LASSO). Discrimination was reported by 
means of internal 10-fold cross-validated (CV) and external 
concordance index (c-index). 
 
Results: The inclusion of OPN and Cyfra 21-1 (hazard ratios of 
3.3 and 1.7) in this clinical model significantly increased the 
c-index from 0.66 to 0.70 (10-fold CV=0.64 and 0.67; c-index 
external =0.62 and 0.66). The calibration slope of the 
prognostic index in the validation cohort was 0.66 (p<0.01), 
therefore requiring re-calibration. Further extension of the 
model by selecting from the 4 additional blood biomarkers 
yielded a c-index of 0.67 (10-fold CV = 0.66), TLR4 was left 
unincluded, and resulted in a better fitting model (likelihood 
ratio test: p=0.01; Table 1). Hypoxia is known to be present 
in NSCLC adversely affecting disease progression and 
response to radiation treatment. Likewise, tumor load is 
often associated with disease development and prognosis. 
The value of hypoxia and tumor load associated markers OPN 
and Cyfra 21-1, was confirmed in this study. Extension of the 
model included α2M, sIL2r, and VEGF, with higher 
concentrations of these new markers being associated with a 
worse prognosis. α2M, a previously identified candidate 
predictor for radiation pneumonitis was found to be a 
prognostic factor in NSCLC. IL-2 was already identified as an 
independent prognostic marker in patients with advanced 
NSCLC. The correlation of IL-2 with shorter survival was 
confirmed in these cohorts and may be of relevance for 
patients receiving IL-2 immunotherapy. Finally, VEGF, the 
angiogenesis factor found in a variety of solid tumors 
including NSCLC, was found to be of added value in the 
extended model. 
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Conclusion: In conclusion, we improved and validated a 
clinical model with inclusion of hypoxia and tumor-load 
related blood-biomarkers. New immunological markers were 
associated with overall survival. Currently we are aiming to 
extend these models to include imaging information 
(Radiomics). 
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Purpose or Objective: Intensity-modulated radiation therapy 
(IMRT) and volumetric-modulated arc therapy (VMAT) are 
widely used in the treatment of advanced stage non-small 
cell lung cancer (NSCLC). These techniques deliver conformal 
dose distributions at the cost of increased target dose 
heterogeneity (particularly IMRT) and larger volumes of 
surrounding healthy tissues receiving low doses (particularly 
VMAT). We evaluated whether these dosimetric differences 
between IMRT and VMAT are of influence on treatment 
toxicity and outcome. 
 
Material and Methods: We retrospectively assessed a cohort 
of 189 consecutive patients with stage III NSCLC having 
undergone radical (chemo-)radiotherapy using IMRT (until 
2011) or VMAT (starting in 2011 ). Most patients (n=182) 
received 66 Gy in 33 (once-daily) fractions to the primary 
tumour and involved hilar/mediastinal lymph nodes based on 
FDG-PET/CT. Concurrent chemoradiation (CCR; n=122) 
consisted of 2 courses of etoposide cisplatinum, whereas 
sequential treatment (n=56) consisted of 3 courses of 
gemcitabine cisplatinum. Acute and late toxicity were 
assessed using the RTOG radiation morbidity scoring criteria 
for esophageal and pulmonary toxicity. Follow-up visits were 
planned every 3 months (first 2 years), biannually thereafter. 
Median overall survival (OS) was calculated using Kaplan-
Meyer survival analysis. Differences between the groups 
receiving IMRT and VMAT were statistically tested using the 
Mann-Whitney-U or Chi-square test, where appropriate. 
 
Results: Gender, age, performance score, clinical (tumour 
and nodal) stage and radiation dose did not significantly 
differ between the IMRT (n=93) and VMAT (n=96) groups. 
Patients undergoing IMRT, however, received less concurrent 
chemotherapy compared to patients treated with VMAT (n=51 
vs n=71; p= 0.007). Incidences of grade ≥2 and ≥3 acute 
esophageal toxicity (AET) were significantly lower for IMRT 
compared to VMAT (28 vs 57 patients, p<0.001; and 6 vs 17 
patients, p=0.025, respectively). Maximum grade acute and 
late pulmonary toxicity did not differ between groups (p=0.57 
and p=0.14, respectively). Grade ≥3 late esophageal toxicity 
was scored in 1 and 3 patients after IMRT and VMAT, 
respectively. Median follow-up for the patients alive was 32 
months (range 2.4-82.1 months). Median OS was 23.9 months 
(95% CI 19.6-28.1), without a significant difference between 
the groups (23.9 and 24.9 months for IMRT and VMAT, 
respectively; p=0.70). 
 
Conclusion: Patients treated with VMAT showed significantly 
higher incidence of Grade ≥2 and ≥3 AET, which may be due 
to a higher percentage of patients receiving CCR in the 
VMAT-group. Median OS did not differ between groups. 
Currently the target volumes and dosimetric data are 
evaluated for differences between the groups, for we 
hypothesized that VMAT enables treatment of larger tumour 
volumes, leading to increased AET. 
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Purpose or Objective: The purpose of the present study was 
to investigate the extent and appearance of early radiologic 
injury in the lung after radiotherapy (RT) for non-small cell 
lung cancer (NSCLC). Furthermore, the ability of planned 
mean lung dose to predict the risk of a radiologic response 
was explored. 
 
Material and Methods: Eligible follow-up computed 
tomography (CT) scans acquired within 6 months after 
commencement of radiotherapy were retrospectively 
evaluated for radiologic injuries in a cohort of 213 NSCLC 
patients treated to 60 or 66 Gy in 2 Gy fractions at a single 
institution from 2007 to 2013. Radiologic injuries were 
divided in two categories based on CT appearance. Category 
1 represented ground-glass opacity (GGO) and interstitial 
changes. Both are characterized by moderately increased 
densities in the lung parenchyma, but where GGO appears 
diffuse, amorphous, and with poorly defined vessel 
structures, interstitial changes are identified by more 
pronounced vessels and borders. Category 2 indicated patchy 
or confluent consolidation in the lung. The volume fraction of 
injured lung corresponding to either category was estimated 
in each scan. To investigate the relationship between the 
volume fraction of injured lung and mean lung dose, a 
logistic regression analysis was performed. Four different cut-
points were chosen to define radiologic injury response. 
These were volume fractions of injured lung larger than 5%, 
10%, 15%, or 20%. Both individual and combined categories 
were investigated. 
 
Results: Radiologic injuries of category 1 and 2 were found in 
follow-up scans for 81% and 42% of the patients, respectively. 
The mean volume fraction of injured lung was 6.5% (range 0-
95%) and 1.7% (range 0-22%) for category 1 and 2, 
respectively, and 8.2% (range 0-95%) when the categories 
were combined. The logistic normal tissue complication 
probability (NTCP) models are shown in the figure for the 
combined categories of lung appearance. The risk of 
radiologic response was found to be significantly associated 
with mean lung dose. The mean lung dose resulting in 50% 
risk of radiologic response (D50) increased from 17 to 29 Gy 
as the cut-point used for dichotomization increased from 5 to 
20% of volume fraction of affected lung (see table). A logistic 
relationship between radiologic response and mean lung dose 
was also found for the individual categories of lung 
